Brentuximab vedotin consolidation post-autologous stem cell transplant in Hodgkin lymphoma patients at risk of residual disease: number needed to treat

References

• Ansell SM. Hodgkin lymphoma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol. 2012;87:1096–1103.
   PubMed Web of Science ®Google Scholar
• Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2013, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2013/, based on November 2015 SEER data submission, posted to the SEER web site, April 2016.
   Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.
   PubMed Web of Science ®Google Scholar
• Borchmann P, Eichenauer DA, Engert A. State of the art in the treatment of Hodgkin lymphoma. Nat Rev Clin Oncol. 2012;9:450–459.
   PubMed Web of Science ®Google Scholar
• Quddus F, Armitage JO. Salvage therapy for Hodgkin’s lymphoma. Cancer J. 2009;15:161–163.
   PubMed Web of Science ®Google Scholar
• Eichenauer DA, Engert A, Andre M, et al. Hodgkin’s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25:iii70–iii75.
   PubMed Web of Science ®Google Scholar
• Crump M. Management of Hodgkin lymphoma in relapse after autologous stem cell transplant. Hematology Am Soc Hematol Educ Program. 2008;2008:326–333.
   Google Scholar
• Majhail NS, Weisdorf DJ, Defor TE, et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin’s lymphoma. Biol Blood Marrow Transplant. 2006;12:1065–1072.
   PubMed Web of Science ®Google Scholar
• Van Den Neste E, Casasnovas O, Andre M, et al. Classical Hodgkin’s lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant. Haematologica. 2013;98:1185–1195.
   PubMed Web of Science ®Google Scholar
• Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102:1458–1465.
   PubMed Web of Science ®Google Scholar
• Wahl AF, Klussman K, Thompson JD, et al. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin’s disease. Cancer Res. 2002;62:3736–3742.
   PubMed Web of Science ®Google Scholar
• Stein H, Delsol G, Pileri SA, et al. Hodgkin Lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France. Vol. 2. 4th ed. 2008. p. 321–334.
   Google Scholar
• Seattle Genetics, Inc. ADCETRIS® (brentuximab vedotin) for Injection. Full prescribing information. Food and Drug Administration. Available at: http://www.seattlegenetics.com/pdf/adcetris_USPI.pdf [Last accessed 20 January 2017].
   Google Scholar
• Takeda Pharma A/S. ADCETRIS® 50 mg powder for concentrate for solution for infusion. Summary of Product Characteristics. European Medicines Agency. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002455/WC500135055.pdf [Last accessed 20 January 2017].
   Google Scholar
• Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385:1853–1862.
   PubMed Web of Science ®Google Scholar
• Sweetenham J, Walewski J, Nademanee AP, et al. Updated efficacy and safety data from the aethera trial of consolidation with brentuximab vedotin after autologous stem cell transplant (ASCT) in Hodgkin lymphoma patients at high risk of relapse. Poster presented at the American Society of Hematology, Orlando, FL, USA, 2015 Abstract 3172.
   Google Scholar
• Barratt A, Wyer PC, Hatala R, et al. Tips for learners of evidence-based medicine: 1. Relative risk reduction, absolute risk reduction and number needed to treat. CMAJ. 2004;171:353–358.
   PubMed Web of Science ®Google Scholar
• Dranitsaris G, Hatzimichael E. Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients. Support Care Cancer. 2012;20:1353–1360.
   PubMed Web of Science ®Google Scholar
• Kaura S, Dranitsaris G. Number needed to treat (NNT) as a measure of drug benefit: lenalidomide versus bortezomib for treatment of relapsed/refractory multiple myeloma (MM). J Clin Oncol. 2012;30:abstract e18562.
   Google Scholar
• Schulz H, Bohlius J, Skoetz N, et al. Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin’s lymphoma. Cochrane Database Syst Rev. 2007;4:CD003805.
   Google Scholar
• Bender R. Calculating confidence intervals for the number needed to treat. Control Clin Trials. 2001;22:102–110.
   PubMedGoogle Scholar
• Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med. 1988;318:1728–1733.
   PubMed Web of Science ®Google Scholar
• McAlister FA. The “number needed to treat” turns 20-and continues to be used and misused. CMAJ. 2008;179:549–553.
   PubMed Web of Science ®Google Scholar
• Guo JJ, Pandey S, Doyle J, et al. A review of quantitative risk-benefit methodologies for assessing drug safety and efficacy-report of the ISPOR risk-benefit management working group. Value Health. 2010;13:657–666.
   PubMed Web of Science ®Google Scholar
• Fahey T, Griffiths S, Peters TJ. Evidence based purchasing: understanding results of clinical trials and systematic reviews. BMJ. 1995;311:1056–1059.
   PubMed Web of Science ®Google Scholar
• Malenka DJ, Baron JA, Johansen S, et al. The framing effect of relative and absolute risk. J Gen Intern Med. 1993;8:543–548.
   PubMed Web of Science ®Google Scholar
• Naylor CD, Chen E, Strauss B. Measured enthusiasm: does the method of reporting trial results alter perceptions of therapeutic effectiveness? Ann Intern Med. 1992;117:916–921.
   PubMed Web of Science ®Google Scholar
• Hildebrandt M, Vervolgyi E, Bender R. Calculation of NNTs in RCTs with time-to-event outcomes: a literature review. BMC Med Res Methodol. 2009;9:21.
   PubMed Web of Science ®Google Scholar
• Nuovo J, Melnikow J, Chang D. Reporting number needed to treat and absolute risk reduction in randomized controlled trials. JAMA. 2002;287:2813–2814.
   PubMed Web of Science ®Google Scholar
• Suissa S. Calculation of number needed to treat. N Engl J Med. 2009;361:424–425.
   PubMed Web of Science ®Google Scholar
• Moskowitz C, Sweetenham J, Chen AI, et al. Brentuximab vedotin after autologous stem cell transplant (ASCT) yields the strongest benefit in Hodgkin lymphoma (HL) patients with ≥2 risk factors: results of a multivariate analysis (MVA). Poster presented at the International Symposium on Hodgkin Lymphoma, Cologne, Germany, 2016 Abstract 0044.
   Google Scholar
• Roth JA, Ramsey SD, Carlson JJ. Cost-effectiveness assessment of brentuximab vedotin to prevent progression following autologous stem cell transplant in Hodgkin lymphoma in the United States. Poster presented at the American Society of Hematology, San Francisco, CA, USA, 2014 Abstract 2657.
   Google Scholar
• Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness–the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371:796–797.
   PubMed Web of Science ®Google Scholar